The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.
本发明涉及小分子化合物及其在治疗细菌感染,特别是结核病方面的用途。
Synthesis, characterization and pharmacological evaluation of (E)-N′-(substituted-benzylidene)isonicotinohydrazide derivatives as potent anticonvulsant agents
作者:Manav Malhotra、Vikramdeep Monga、Sagun Sharma、Jainendra Jain、Abdul Samad、James Stables、Aakash Deep
DOI:10.1007/s00044-011-9739-5
日期:2012.9
also evaluated in the minimal clonic seizure model and exhibited potentanticonvulsant activity with lower neurotoxicity. Among all synthesized derivatives, analogue 3a was found to exhibit protection in MES and scPTZ seizure models. This study proved that isonicotinoyl hydrazides synthesized by condensing isoniazid with various aldehydes and ketones displayed moderate to potentanticonvulsant activity
Isonicotinohydrazones as inhibitors of alkaline phosphatase and ecto-5′-nucleotidase
作者:Pervaiz Ali Channar、Syed Jawad Ali Shah、Sidra Hassan、Zaib un Nisa、Joanna Lecka、Jean Sévigny、Jürgen Bajorath、Aamer Saeed、Jamshed Iqbal
DOI:10.1111/cbdd.12861
日期:2017.3
ecto-5'-nucleotidases (h-e5'NT & r-e5'NT) and alkalinephosphatase isozymes including both bovine tissue-nonspecific alkalinephosphatase (b-TNAP) and tissue specific calfintestinalalkalinephosphatase (c-IAP). These enzymes are implicated in vascular calcifications, hypophosphatasia, solid tumors and cancers, such as colon, lung, breast, pancreas and ovary. All tested compounds were active against both enzymes
Sah; Peoples, Journal of the American Pharmaceutical Association (1912), 1954, vol. 43, p. 513,514
作者:Sah、Peoples
DOI:——
日期:——
(Hetero-)(arylidene)arylhydrazides as Multitarget-Directed Monoamine Oxidase Inhibitors
作者:Ashique Palakkathondi、Jong Min Oh、Sanal Dev、T. M. Rangarajan、Swafvan Kaipakasseri、Fathima Sahla Kavully、Nicola Gambacorta、Orazio Nicolotti、Hoon Kim、Bijo Mathew
DOI:10.1021/acscombsci.0c00136
日期:2020.11.9
Fourteen (hetero-)(arylidene)arylhydrazide derivatives (ABH1-ABH14) were synthesized, and their inhibitory activities against monoamine oxidases (MAOs) and acetylcholinesterase (AChE) were evaluated. Compound ABHS most potently inhibited MAO-B with an IC50 value of 0.025 +/- 0.0019 mu M; ABH2 and ABH3 exhibited high IC so values as well. Most of the compounds weakly inhibited MAO-A, except ABHS (IC50 = 3.31 +/- 0.41 mu M). Among the active compounds, ABH2 showed the highest selectivity index (SI) of 174 for MAO-B, followed by ABHS (SI = 132). ABH3 and ABHS effectively inhibited AChE with IC so values of 15.7 +/- 6.52 and 16.5 +/- 7.29 mu M, respectively, whereas the other compounds were weak inhibitors of AChE. ABHS was shown to be a reversible competitive inhibitor for MAO-A and MAO-B with K-i values of 0.96 +/- 0.19 and 0.024 +/- 0.0077 mu M, respectively, suggesting that this molecule can be considered as an interesting candidate for further development as a multitarget inhibitor relating to neurodegenerative disorders.